Source: CureToday articles
INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer.
Recent Content
- Asembia AXS25: Pharmacy Perspectives on the Inflation Reduction Act
- An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC
- AACR 2025: Orally Bioavailable RIPTAC Therapeutic Targets p53-Y220C Mutant Tumors for Selective Cancer Cell Death
- Investigating the Addition of Surgery to ICI Therapy in Kidney Cancer
- Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
- TAR-200 Shows High Response Rates in Bladder Cancer Subset
- A Fellow Cancer Survivor Gives Me a Useful Message
- AACR 2025: Tailored Treatment Guided by Combined Tissue and Liquid Biopsies May Improve Outcomes in Advanced Solid Tumors
- FDA Approves Upadacitinib for Adult Patients With Giant Cell Arteritis
- FDA Approves Prademagene Zamikeracel, First and Only Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa